Impact of Covid-19 Pandemic on Children With Neuromuscular Disease and Their Parents in Turkey: Parent Perspective

Sponsor
Hacettepe University (Other)
Overall Status
Completed
CT.gov ID
NCT05771727
Collaborator
(none)
134
1
3
44.3

Study Details

Study Description

Brief Summary

Parents of children with neuromuscular disease have been already at risk of depression, anxiety and burden. Additionally, the daily lives of children with neuromuscular disease and their parents have been significantly affected by the COVID-19 pandemic. Therefore, this study investigated parents' perspective on the effect of the COVID-19 pandemic on children with neuromuscular diseases and themselves.

Condition or Disease Intervention/Treatment Phase
  • Other: survey

Detailed Description

The 55-item survey created by the researchers was applied online to determine the psychological and physical effects of COVID-19 on neuromuscular patients and their families. This survey also included the Content of the 9-Item Caregiver COVID-19 Limitations Scale (CCLS-9).

Study Design

Study Type:
Observational
Actual Enrollment :
134 participants
Observational Model:
Family-Based
Time Perspective:
Prospective
Official Title:
Impact of Covid-19 Pandemic on Children With Neuromuscular Disease and Their Parents in Turkey: Parent Perspective
Actual Study Start Date :
Jul 1, 2021
Actual Primary Completion Date :
Aug 1, 2021
Actual Study Completion Date :
Oct 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Parents of children with pediatric neuromuscular diseases

Parents of a total of 169 children with pediatric neuromuscular diseases, including 63 Duchnenne Muscular Dystrophy, 53 Spinal Muscular Atrophy and 18 other pediatric neuromuscular diseases (Congenital Muscular Dystrophy, Hereditary Motor and Sensory Neuropathy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, etc.) were included in the study

Other: survey
The 55-item survey created by the researchers was applied online to determine the psychological and physical effects of COVID-19 on neuromuscular patients and their families. This survey also included the Content of the 9-Item Caregiver COVID-19 Limitations Scale (CCLS-9).

Outcome Measures

Primary Outcome Measures

  1. The questionnaire which created by the researchers [30 minutes]

    The 55-item survey created by the researchers was applied online to determine the psychological and physical effects of COVID-19 on neuromuscular patients and their families.

Secondary Outcome Measures

  1. Content of the 9-Item Caregiver COVID-19 Limitations Scale (CCLS-9) [5 minutes]

    This scale consists of 9 items and has a scoring system between 1-10 for each item which is chosen by the caregiver. According to the CCLS-9 scale, the lowest anxiety, stress or burden of the caregiver scored as 1 while the highest level was 10.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • taking care for a child with NMD whose age was between 0-18 years,

  • having the ability to read and write Turkish language,

  • having access to phone or e-mail,

  • being volunteer.

Exclusion Criteria:
  • having a child who have an additional diagnosis besides NMD and taking care of any other person in the family.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hacettepe University Ankara Turkey 06680

Sponsors and Collaborators

  • Hacettepe University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Merve Bora, Physiotherapist, Hacettepe University
ClinicalTrials.gov Identifier:
NCT05771727
Other Study ID Numbers:
  • GO 21/722
First Posted:
Mar 16, 2023
Last Update Posted:
Mar 16, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 16, 2023